Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We herein develop two β-galactosidase (β-Gal) activatable NIR fluorescent probes for visualizing ovarian cancers. Particularly, probe BOD-M-βGal produced NIR-II emission light at 900-1300 nm upon β-Gal activation. By using our activatable and target specific NIR-II probe for deep-tissue imaging of β-Gal overexpressed ovarian cancer cells, rapid and accurate imaging of ovarian tumors in nude mice was achieved.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c9cc09158k | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Review on Biomarker-Enhanced Machine Learning for Early Diagnosis and Outcome Prediction in Ovarian Cancer Management.
Cancer Med
September 2025
Department of Computer Engineering, Social and Biological Network Analysis Laboratory, University of Kurdistan, Sanandaj, Iran.
Background: Ovarian cancer (OC) remains the most lethal gynecological malignancy, largely due to its late-stage diagnosis and nonspecific early symptoms. Advances in biomarker identification and machine learning offer promising avenues for improving early detection and prognosis. This review evaluates the role of biomarker-driven ML models in enhancing the early detection, risk stratification, and treatment planning of OC.
View Article and Find Full Text PDFAuthor Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Nat Commun
September 2025
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, 90033, California, USA.
Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine.
Cancer Med
September 2025
Department of Radiology & Nuclear Medicine, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, the Netherlands.
Aims: This review summarizes the role and future prospects of nuclear medicine in ovarian cancer, focusing on novel radiopharmaceuticals beyond FDG for diagnostic, predictive, and therapeutic applications within a theranostic framework.
Materials And Methods: A narrative literature review was conducted using major databases. Peer-reviewed articles addressing non-FDG radiopharmaceuticals in ovarian cancer were identified and assessed; FDG-based studies were excluded due to the availability of prior comprehensive reviews.
Recurrent Malignant Struma Ovarii With Peritoneal Implants Following Prior Thyroid Carcinoma Treatment.
Cureus
August 2025
Faculty of Medicine, University of Costa Rica, San José, CRI.
Struma ovarii (SO) is a rare form of ovarian teratoma predominantly composed of thyroid tissue. While most cases follow a benign course, some may exhibit malignant transformation or extra-ovarian spread. We present the case of a 43-year-old woman with a history of SO previously treated with right oophorectomy and systemic chemotherapy, along with a separate diagnosis of papillary thyroid carcinoma managed with total thyroidectomy and radioactive iodine ablation.
View Article and Find Full Text PDFEvaluating the Efficacy of Mebendazole Repurposing for Ovarian Cancer Therapy Using Optical Coherence Tomography.
J Biophotonics
September 2025
Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, USA.
Ovarian cancer (OvCa) remains the leading cause of gynecological cancer mortality, with most patients developing chemoresistance. Drug repurposing offers promising alternatives, with mebendazole (MBZ) showing anticancer activity. This study evaluates MBZ efficacy using Spectral Domain Optical Coherence Tomography (SD-OCT).
View Article and Find Full Text PDF